Skip to main content
    K

    Kymera Therapeutics Inc (KYMR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $125.85
    -1.72 (-1.35%)

    Market Cap: $10.89B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kymera Therapeutics Inc (KYMR) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Kymera Therapeutics (KYMR) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Kymera Therapeutics reported EPS of -$1.32, below the -$1.26 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    36%(9/25)
    Avg Surprise
    -39.89%

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.33
    Range-$1.51 - -$0.82
    27 analysts
    Revenue Consensus
    $545.99K
    RangeN/A
    24 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.35
    Range-$1.52 - -$1.08
    7 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.06-27.4%
    60d ago-$1.26-7.6%
    30d ago-$1.36+0.9%
    7d ago-$1.36+0.4%
    Current-$1.35
    Revenue Consensus
    $7.00M
    RangeN/A
    6 analysts

    Next Report

    KYMR has an expected report date of Feb 24, 2027.

    KYMR Earnings Call

    The latest KYMR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 25 quarters below that had an estimate, KYMR beat 9 and missed 16. The widest gap in the table came in the quarter ended Dec 31, 2020, when EPS landed 625.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.32-$1.26-$1.47 - -$1.04-4.76%MissN/A212 up, 11 downOct 29, 2026N/A
    Jun 30, 2026-$0.62-$0.64-$1.42 - -$0.27+3.13%BeatN/A212 up, 0 downAug 5, 2026$65.00M
    Mar 31, 2026-$0.71-$0.86-$1.03 - -$0.58+17.44%BeatN/A196 up, 4 downApr 30, 2026$34.37M
    Dec 31, 2025-$0.97-$0.77-$0.98 - -$0.41-25.97%MissN/A191 up, 2 downFeb 26, 2026$2.87M
    Sep 30, 2025-$0.94-$0.78-$1.15 - $0.18-20.51%MissN/A201 up, 0 downNov 4, 2025$2.76M
    Jun 30, 2025-$0.95-$0.80-$1.08 - -$0.31-18.75%MissN/A163 up, 0 downAug 11, 2025$11.48M
    Mar 31, 2025-$0.82-$0.91-$1.07 - -$0.76+9.89%BeatN/A140 up, 1 downMay 9, 2025$22.10M
    Dec 31, 2024-$0.89-$0.79-$1.01 - -$0.08-12.92%MissN/A1611 up, 1 downFeb 27, 2025$7.39M
    Sep 30, 2024-$0.82-$0.84-$1.02 - -$0.67+2.38%BeatN/A160 up, 0 downOct 31, 2024$3.74M
    Jun 30, 2024-$0.58-$0.66-$0.81 - -$0.40+12.12%BeatN/A150 up, 0 downAug 7, 2024$25.65M
    Mar 31, 2024-$0.62-$0.72-$0.87 - -$0.57+13.89%BeatN/A130 up, 0 downMay 2, 2024$10.29M
    Dec 31, 2023-$0.25-$0.40-$0.86 - $0.45+37.50%BeatN/A160 up, 0 downFeb 22, 2024$47.88M
    Sep 30, 2023-$0.90-$0.70-$0.90 - -$0.47-28.57%MissN/A140 up, 0 downNov 2, 2023$4.73M
    Jun 30, 2023-$0.67-$0.74-$0.86 - -$0.24+9.46%BeatN/A140 up, 0 downAug 3, 2023$16.51M
    Mar 31, 2023-$0.70-$0.69-$0.83 - -$0.42-1.45%MissN/A130 up, 0 downMay 4, 2023$9.47M
    Dec 31, 2022-$0.60-$0.63-$0.92 - $0.39+4.76%BeatN/A150 up, 0 downFeb 23, 2023$16.14M
    Sep 30, 2022-$0.79-$0.75-$1.03 - -$0.44-5.33%MissN/A130 up, 0 downNov 3, 2022$9.55M
    Jun 30, 2022-$0.78-$0.69-$0.93 - -$0.60-13.04%MissN/A100 up, 0 downAug 9, 2022$11.51M
    Mar 31, 2022-$0.71-$0.67-$0.90 - -$0.25-5.97%MissN/A81 up, 0 downMay 3, 2022$9.62M
    Dec 31, 2021-$0.66-$0.57-$0.73 - -$0.28-15.79%MissN/A10N/AFeb 24, 2022$15.28M
    Sep 30, 2021-$0.56-$0.37-$0.59 - -$0.22-51.35%MissN/A8N/ANov 10, 2021$20.34M
    Jun 30, 2021-$0.55-$0.25-$0.42 - -$0.12-120.00%MissN/A6N/AAug 6, 2021$18.52M
    Mar 31, 2021-$0.29-$0.20-$0.39 - $0.12-45.00%MissN/A6N/AMay 6, 2021$18.70M
    Dec 31, 2020-$0.29-$0.04-$0.24 - $0.46-625.00%MissN/A5N/AMar 11, 2021$12.79M
    Sep 30, 2020-$0.39$2.91N/A-113.40%MissN/A1N/ANov 5, 2020$14.53M
    Jun 30, 2020-$0.42N/AN/AN/AN/AN/AN/AN/AAug 21, 2020$3.29M
    Mar 31, 2020-$0.96N/AN/AN/AN/AN/AN/AN/AJun 29, 2020$3.43M
    Last 27 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.68, after -$2.91 the year before. It was -$2.06 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.68N/A
    Dec 31, 2024-$2.91N/A
    Dec 31, 2023-$2.52N/A
    Dec 31, 2022-$2.88N/A
    Dec 31, 2021-$2.06N/A
    Dec 31, 2020-$2.06N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,900 words across 27 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,85427
    2026Q2Jun 30, 20266,88425
    2025Q4Dec 31, 20258,47920
    2025Q3Sep 30, 20257,80418
    2025Q2Jun 30, 20256,08311
    2025Q1Mar 31, 20258,45017
    2024Q4Dec 31, 20248,22821
    2024Q3Sep 30, 20247,06716

    2026Q3 Earnings Call

    Opening remarks

    Justine Koenigsberg Vice President of Investor Relations Good morning, and welcome to Kymera's quarterly update call, which will also include a discussion of the KT-579 Phase I healthy volunteer results. Joining me this morning with prepared remarks are Nello Mainolfi, our Founder, President and CEO; Terence Rooney, our Chief Medical Officer; and Bruce Jacobs, our Chief Financial Officer. Following our prepared remarks, we will open the call for questions from our covering analysts. In order to have as much time for as many questions as possible, please limit your questions to one. If you would like to ask a question, please use the raise hand icon, which can be found at the bottom of your meeting window. A replay of today's call, including a copy of the corresponding presentation, will be available in the Investors section of our website soon after the call concludes. As a reminder, today's presentation will include forward-looking statements about our future expectations, plans and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. A description of these risks can be found in our most recent 10-Q filed with the SEC. Any forward-looking statements speak only as of today's date, and we assume no obligation to update any forward-looking statements made on today's call. Before we begin, we have one housekeeping item. Starting next week, we will enter our previously planned quiet period ahead of our upcoming STAT6 data. As a result, we don't expect to provide additional commentary on our STAT6 program until we report those results. With that, I will turn the discussion over to Nello.

    Nello Mainolfi Founder, President and CEO Thank you, Justine, and good morning, everyone. Thank you for joining us today. This is a very exciting time for Kymera. We're seeing our scientific vision take shape across our pipeline of oral medicines to address serious inflammatory diseases with KT-621, our STAT6 degrader for atopic dermatitis, asthma and more, and KT-579, our IRF5 degrader for lupus and potentially other autoimmune diseases. Together, they reflect our goal of developing medicines grounded in strong biology with the potential to reach many more patients than are served by available treatments today. I'll start today with an update on KT-621 as we approach its Phase IIb AD readout before year-end. I'll then briefly cover the rest of our pipeline before we turn to KT-579 Phase I results. Our STAT6 program continues to advance according to plan across both AD and asthma. As shown here, we've advanced KT-621 through a series of studies, building on what we learned at each stage to guide the next steps.

    Frequently Asked Questions About KYMR

    When is Kymera Therapeutics's next earnings date?

    Kymera Therapeutics's next earnings report is expected for Feb 24, 2027.

    Did KYMR beat earnings estimates last quarter?

    No. Kymera Therapeutics reported EPS of -$1.32 for the quarter ended Sep 30, 2026, below the -$1.26 estimate by 4.76%.

    What EPS do analysts expect from KYMR next quarter?

    The consensus EPS estimate for Kymera Therapeutics for the quarter ending Dec 31, 2026 is -$1.33 from 27 analysts, with estimates from -$1.51 to -$0.82.

    How often does KYMR beat earnings estimates?

    Kymera Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -6.56%.